We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Osiris Therapeutics has announced positive six-month results from a Phase I clinical trial evaluating Provacel, an adult mesenchymal stem cell therapy for the treatment of heart disease.
BioCryst announced it is voluntarily placing on hold its Phase IIb clinical trial of intravenous Fodosine in the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoma.
CombinatoRx has announced preliminary results of a Phase II clinical trial studying CRx-139 (a synergistic combination of 3 mg of prednisolone and the antidepressant paroxetine) and 3 mg of prednisolone alone in patients with rheumatoid arthritis (RA).
Barrier Therapeutics announced positive results from its completed Phase IIb dose-ranging study for its novel oral antifungal product candidate pramiconazole.
Otsuka has announced trial results showing that once-daily dosing with its investigational oral medication tolvaptan, a vasopressin receptor antagonist, was associated with improvements in signs and symptoms of acutely decompensated heart failure (ADHF) in hospitalized patients receiving conventional care, without an adverse effects on their long-term survival, versus placebo.
Eli Lilly announced that the European Medicines Agency (EMEA) has granted orphan drug designation to enzastaurin, its investigational, multitargeted, oral cancer agent, for the treatment of diffuse large B-cell lymphoma (DLBCL).
Cleveland Clinic researchers announced they have recently completed a pair of studies to determine the safety and efficacy of a new, potent type of cholesterol treatment known as a peroxisome proliferator-activated receptor alpha (PPAR-alpha) agonist.